Cargando…

Helicobacter pylori and Respiratory Diseases: 2021 Update

Helicobacter pylori (H. pylori) is a Gram-negative bacterium involved in the development of gastritis, peptic ulcer disease, gastric adenocarcinoma, and gastric mucosa-associated lymphoid tissue. Unexplained iron deficiency anemia, idiopathic thrombocytopenic purpura and vitamin B12 deficiency have...

Descripción completa

Detalles Bibliográficos
Autores principales:	Durazzo, Marilena, Adriani, Alessandro, Fagoonee, Sharmila, Saracco, Giorgio Maria, Pellicano, Rinaldo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8537719/ https://www.ncbi.nlm.nih.gov/pubmed/34683354 http://dx.doi.org/10.3390/microorganisms9102033

Ejemplares similares

Response to: Reply on “Renewed Helicobacter pylori Management and Therapy in 2015”
por: Fagoonee, Sharmila, et al.
Publicado: (2016)

Rifabutin-Based Rescue Therapy for Helicobacter pylori Eradication: A Long-Term Prospective Study in a Large Cohort of Difficult-to-Treat Patients
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

One or Two Weeks of Treatment with Helicobacter pylori “Standard” Triple Therapy in the Year 2015?
por: Pellicano, Rinaldo, et al.
Publicado: (2015)

A Retrospective Experience of Helicobacter pylori Histology in a Large Sample of Subjects in Northern Italy
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Trends in the Comprehension and Management of Gastrointestinal Tract Disorders
por: Durazzo, Marilena, et al.
Publicado: (2022)

Extra-Intestinal Manifestations of Celiac Disease: What Should We Know in 2022?
por: Durazzo, Marilena, et al.
Publicado: (2022)

Comment on Helicobacter pylori seroprevalence and the occurrence and severity of psoriasis
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2017)

Autoimmune Hepatitis and Fibrosis
por: Pellicano, Rinaldo, et al.
Publicado: (2023)

2013 Update on Celiac Disease and Eosinophilic Esophagitis
por: Pellicano, Rinaldo, et al.
Publicado: (2013)

Amoxycillin and Metronidazole Therapy for Helicobacter pylori Eradication: A 10-Year Trend in Turin, Italy
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2017)

Helicobacter pylori eradication: the relevance of a periodic update
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis
por: Carli, Edoardo, et al.
Publicado: (2020)

Response to: Comment on “Efficacy of 7-Day and 14-Day Triple Therapy Regimens for the Eradication of Helicobacter pylori: A Comparative Study in a Cohort of Romanian Patients”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2016)

The Evolving Incidence of Hepatitis C Virus Infection in Italy
por: Pellicano, Rinaldo, et al.
Publicado: (2012)

Promises of Fibroblast Growth Factor Receptor–Directed Therapy in Tailored Cancer Treatment
por: Fagoonee, Sharmila, et al.
Publicado: (2020)

Does the Microbiota Play a Pivotal Role in the Pathogenesis of Irritable Bowel Syndrome?
por: Fagoonee, Sharmila, et al.
Publicado: (2019)

History of Inflammatory Bowel Diseases
por: Actis, Giovanni Clemente, et al.
Publicado: (2019)

Extra-Esophageal Presentation of Gastroesophageal Reflux Disease: 2020 Update
por: Durazzo, Marilena, et al.
Publicado: (2020)

Infections with Helicobacter pylori and challenges encountered in Africa
por: Smith, Stella, et al.
Publicado: (2019)

Management of Dyspepsia and Gastroparesis in Patients with Diabetes. A Clinical Point of View in the Year 2021
por: Bonetto, Silvia, et al.
Publicado: (2021)

Is there a low prevalence of Helicobacter pylori infection in Jordanian patients with gastric cancer?
por: Pellicano, Rinaldo
Publicado: (2017)

Etiology of chronic liver diseases in the Northwest of Italy, 1998 through 2014
por: Saracco, Giorgio Maria, et al.
Publicado: (2016)

Strategies for Helicobacter pylori eradication in the year 2020
por: Pellicano, Rinaldo, et al.
Publicado: (2020)

Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity (“lymphocytic enterocolitis”)?
por: Bonagura, Gabriele Antonio, et al.
Publicado: (2016)

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
por: Bertani, Lorenzo, et al.
Publicado: (2020)

Which should be the first-line treatment for Helicobacter pylori in Colombia? A lesson from a recent study
por: Pellicano, Rinaldo
Publicado: (2019)

Evolving Cell-Based and Cell-Free Clinical Strategies for Treating Severe Human Liver Diseases
por: Cernigliaro, Viviana, et al.
Publicado: (2020)

Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Primary Biliary Cholangitis and Bile Acid Farnesoid X Receptor Agonists
por: Abenavoli, Ludovico, et al.
Publicado: (2020)

Comment on “Advanced Hepatic Fibrosis in Fatty Liver Disease Linked to Hyperplastic Colonic Polyp”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2017)

Comment on: Jeon et al. Helicobacter pylori Infection Is Associated With an Increased Rate of Diabetes. Diabetes Care 2012;35:520–525
por: Eshraghian, Ahad, et al.
Publicado: (2013)

Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2020)

On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Updated Helicobacter pylori Management in 2015
por: Abadi, Amin Talebi Bezmin
Publicado: (2016)

Update on the Management of Helicobacter pylori Infection
por: Saleem, Nasir, et al.
Publicado: (2020)

Update on triple therapy for eradication of Helicobacter pylori: current status of the art
por: Urgesi, Riccardo, et al.
Publicado: (2012)

Clinical Response and Changes of Cytokines and Zonulin Levels in Patients with Diarrhoea-Predominant Irritable Bowel Syndrome Treated with Bifidobacterium Longum ES1 for 8 or 12 Weeks: A Preliminary Report
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Antibiotic susceptibility, heteroresistance, and updated treatment strategies in Helicobacter pylori infection
por: Mascellino, Maria Teresa, et al.
Publicado: (2017)

Current understanding and management of Helicobacter pylori infection: an updated appraisal
por: Ansari, Shamshul, et al.
Publicado: (2018)

Virulence of Helicobacter pylori outer membrane proteins: an updated review
por: Xu, Chenjing, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qjd3vkki7lgj0vpn0ql3s6uh6v